摘要
目的探讨血清鳞状细胞癌抗原(SCCA)、细胞角蛋白19片段(CYFRA21-1)对晚期肺癌患者骨转移的预测价值。方法抽取濮阳油田总医院于2020年1月至2022年4月收治的非骨转移的晚期肺癌患者178例。所有患者入院后均通过化学发光法检测血清SCCA、CYFRA21-1水平。所有患者入院后完善相关检查,明确病理类型、临床分期及转移情况,对患者全身情况进行整体评估,给予其综合治疗。通过影像学或病理检查明确所有晚期肺癌患者随访6个月内骨转移发生情况,分析发生骨转移和未发生骨转移患者的血清SCCA、CYFRA21-1水平差异,探讨其在晚期肺癌患者骨转移中的预测价值。结果随访6个月内,178例晚期肺癌患者中发生骨转移39例(21.91%,39/178),未发生骨转移139例(78.09%,139/178)。发生骨转移者血清SCCA、CYFRA21-1水平高于未发生骨转移者(P<0.05);二者基线资料比较差异未见统计学意义(P>0.05)。经Logistic回归分析结果显示,血清SCCA、CYFRA21-1与晚期肺癌患者骨转移的发生有关(OR>1,P<0.05)。绘制受试者工作特征曲线结果显示,血清SCCA、CYFRA21-1预测晚期肺癌骨转移发生结局的曲线下面积分别为0.766、0.865,说明其具有一定的预测功能。结论血清SCCA、CYFRA21-1对晚期肺癌患者骨转移具有预测价值,其值越高,发生骨转移的概率越大。
Objective To investigate the predictive value of serum squamous cell carcinoma antigen(SCCA)and cytokeratin 19 fragment(CYFRA21-1)for bone metastasis in patients with advanced lung cancer.Methods A total of 178 patients with advanced lung cancer without bone metastasis admitted to Puyang Oilfield General Hospital from January 2020 to April 2022 were selected.After admission,the levels of serum SCCA and CYFRA21-1 of all patients were measured by chemiluminescence method.All patients underwent comprehensive examination after admission,and the pathological type,clinical stage and metastasis were determined.The overall condition of the patients was evaluated,and the comprehensive treatment was given.The incidence of bone metastasis within 6 months of follow-up in all patients with advanced lung cancer was determined by imaging or pathological examination.The differences of serum SCCA and CYFRA21-1 levels between patients with and without bone metastasis were analyzed,and their value in predicting bone metastasis of patients with advanced lung cancer was discussed.Results During 6 months of follow-up,39 of 178 patients with advanced lung cancer had bone metastasis,accounting for 21.91%(39/178),and 139 cases had no bone metastasis,accounting for 78.09%(139/178).The levels of serum SCCA and CYFRA21-1 in patients with bone metastasis were significantly higher than those in patients without bone metastasis(P<0.05).There was no statistical significant difference in baseline data between the two groups(P>0.05).Results of Logistic regression analysis showed that serum SCCA,CYFRA21-1 were associated with bone metastasis in patients with advanced lung cancer(OR>1,P<0.05).Results of the receiver operating characteristic curve showed that the area under the curve of serum SCCA and CYFRA21-1 for predicting the outcome of bone metastasis from advanced lung cancer were 0.766 and 0.865,respectively,indicating that it had certain predictive function.Conclusions Serum SCCA and CYFRA21-1 have predictive value for bone metastasis in patients with advanced lung cancer.The higher the value is,the greater the probability of bone metastasis is.
作者
魏侠
Wei Xia(Department of Clinical Laboratory,Puyang Oilfield General Hospital,Puyang 457001,China)
出处
《中国实用医刊》
2023年第5期31-34,共4页
Chinese Journal of Practical Medicine
关键词
肺癌
晚期
骨转移
鳞状细胞癌抗原
细胞角蛋白19片段
Lung cancer
Advanced
Bone metastasis
Squamous cell carcinoma antigen
Cytokeratin 19 fragment
